AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7991935 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of 30 cm VD with 60 cm VD
Number of subjects: 15
Study 2511693 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg nitroglycerin intravenously
Number of subjects: 54
Study 2511693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 4544476 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarizing solution: continuous intravenous perfusion during 7 days of one liter daily of a 10% glucose solution with potassium (40 m Eq/L) and insulin (20 units)
Number of subjects: 174
Study 4544476 — intervention group
Group type: COMPARATOR
Intervention: Control group: slow perfusion (one liter daily) of a 5% glucose solution
Number of subjects: 174
Study 4544476 — intervention group
Group type: COMPARATOR
Intervention: Both groups (polarized and control)
Number of subjects: 174
Study 31602699 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft alone
Number of subjects: 14
Study 31602699 — intervention group
Group type: COMPARATOR
Intervention: Composite graft (autogenous bone chips and xenograft)
Number of subjects: 14
Study 31480755 — intervention group
Group type: EXPERIMENTAL
Intervention: TransGender Specific Course and Workshop (TGSC&W) with film-forum methodology (G1)
Number of subjects: 116
Study 31480755 — intervention group
Group type: EXPERIMENTAL
Intervention: TransGender Specific Course and Workshop (TGSC&W) with problem-based learning (PBL) methodology (G2)
Number of subjects: 116
Study 31480755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific classes or workshops)
Number of subjects: 116
Study 31480755 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between film-forum and PBL methodologies
Number of subjects: 116
Study 31480755 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with learning methodology
Number of subjects: 116
Study 28700892 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Active Living for Diabetes and Gestational Diabetes Mellitus (HEALD‐GDM) program, 24-week program led by an Exercise Specialist
Number of subjects: 100
Study 28700892 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study 26279580 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg/kg)
Number of subjects: 14
Study 26279580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg)
Number of subjects: 14
Study 24490265 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin
Number of subjects: 5947
Study 24490265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5947
Study 20962338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (HDT) pretreatment
Number of subjects: 984
Study 20962338 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 984
Study 20962338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bail-out use of study medication
Number of subjects: 984
Study 20962338 — intervention group
Group type: EXPERIMENTAL
Intervention: HDT bail-out
Number of subjects: 984
Study 20962338 — intervention group
Group type: COMPARATOR
Intervention: Placebo bail-out in patients pretreated with HDT
Number of subjects: 984
Study 18328334 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (specific pharmacologic treatment not detailed)
Number of subjects: 126
Study 18328334 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no specific intervention mentioned)
Number of subjects: 126
Study 18328334 — intervention group
Group type: COMPARATOR
Intervention: On treatment (no specific intervention mentioned)
Number of subjects: 126
Study 16416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy agents (PTA) applied five times a week for 3 weeks
Number of subjects: 80
Study 16416102 — intervention group
Group type: COMPARATOR
Intervention: Hylan G-F 20 or sodium hyaluronate (NaHA) administered weekly intra-articular during the first 3 weeks and in the sixth month
Number of subjects: 80
Study 14735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine
Number of subjects: 68
Study 14735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine and 15 mg fentanyl
Number of subjects: 68
Study 14735021 — intervention group
Group type: COMPARATOR
Intervention: Natural delivery
Number of subjects: 68
Study 14735021 — intervention group
Group type: COMPARATOR
Intervention: Caesarean delivery with general anaesthesia
Number of subjects: 68
Study 11054156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 7
Study 8615356 — intervention group
Group type: COMPARATOR
Intervention: Synthetic beta-carotene (40 mg daily for 14 days)
Number of subjects: 0
Study 8615356 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta-carotene from Dunaliella bardawil (40 mg daily for 14 days)
Number of subjects: 0
Study 1417224 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless pericardial valves
Number of subjects: 57
Study 1417224 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless valves
Number of subjects: 57
Study 6706069 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day clear liquid diet with laxatives and enemas
Number of subjects: 197
Study 6706069 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day minimum-residue diet with laxatives and enemas
Number of subjects: 197
Study 6706069 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day minimum-residue diet with laxatives and enemas
Number of subjects: 197
Study 6706069 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely
Number of subjects: 197
Study 6706069 — intervention group
Group type: COMPARATOR
Intervention: Breath hydrogen and methane levels in group 3
Number of subjects: 197
Study 6706069 — intervention group
Group type: COMPARATOR
Intervention: Breath hydrogen and methane levels in group 4
Number of subjects: 197
Study 6706069 — intervention group
Group type: COMPARATOR
Intervention: Hematologic and biochemical parameters
Number of subjects: 197
Study 31241491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nifedipine 3% ointment
Number of subjects: 200
Study 31241491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30328547 — intervention group
Group type: EXPERIMENTAL
Intervention: PFA‐7 at 2% of dry matter intake (DMI)
Number of subjects: 21
Study 30328547 — intervention group
Group type: EXPERIMENTAL
Intervention: PFA‐7 at 4% of dry matter intake (DMI)
Number of subjects: 21
Study 30328547 — intervention group
Group type: COMPARATOR
Intervention: Control (without PFA‐7)
Number of subjects: 21
Study 29297588 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for lichen planopilaris
Number of subjects: 32
Study 27642172 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended magnetic resonance imaging (eMRI) scale
Number of subjects: 0
Study 25318000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol & sufentanil (PS) group received 0.1 μg/kg sufentanil and 1-2 mg/kg propofol
Number of subjects: 439
Study 25318000 — intervention group
Group type: COMPARATOR
Intervention: Propofol & fentanyl (PF) group received 1 μg/kg fentanyl and 1-2 mg/kg propofol
Number of subjects: 439
Study 25318000 — intervention group
Group type: COMPARATOR
Intervention: Propofol & remifentanil (PR) group received 1 μg/kg remifentanil and 1-2 mg/kg propofol
Number of subjects: 439
Study 25318000 — intervention group
Group type: COMPARATOR
Intervention: Propofol & half-fentanil (Pf) group received 0.5 μg/kg fentanyl and 1-2 mg/kg propofol
Number of subjects: 439
Study 25318000 — intervention group
Group type: COMPARATOR
Intervention: Propofol & half-sufentanil (Ps) group received 0.05 μg/kg sufentanil and 1-2 mg/kg propofol
Number of subjects: 439
Study 25318000 — intervention group
Group type: COMPARATOR
Intervention: Propofol & half-remifentanil (Pr) group received 0.5 μg/kg remifentanil and 1-2 mg/kg propofol
Number of subjects: 439
Study 22318246 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) plus reduced-exposure cyclosporine A (CsA)
Number of subjects: 30
Study 22318246 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CsA
Number of subjects: 30
Study 20488408 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 334
Study 20488408 — intervention group
Group type: COMPARATOR
Intervention: Surgical endarterectomy (CEA)
Number of subjects: 334
Study 18588360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-cycling bipolar I disorder
Number of subjects: 245
Study 18588360 — intervention group
Group type: COMPARATOR
Intervention: Rapid-cycling bipolar II disorder
Number of subjects: 245
Study 15830389 — intervention group
Group type: COMPARATOR
Intervention: Skin-prick testing (SPT) in children aged 2-<5 years
Number of subjects: 149
Study 15830389 — intervention group
Group type: COMPARATOR
Intervention: Skin-prick testing (SPT) in children aged 5-10 years
Number of subjects: 149
Study 11819152 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drug withdrawal
Number of subjects: 21
Study 10909492 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound examination
Number of subjects: 306
Study 10909492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 306
Study 7481852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0
Study 7481852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens
Number of subjects: 0
Study 7481852 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent regimens
Number of subjects: 0
Study 2023020 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple notification of primary care provider (n = 102)
Number of subjects: 292
Study 2023020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive notification (n = 104)
Number of subjects: 292
Study 2023020 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 292
Study 7342654 — intervention group
Group type: EXPERIMENTAL
Intervention: AR programme
Number of subjects: 30
Study 7342654 — intervention group
Group type: COMPARATOR
Intervention: RAMP programme
Number of subjects: 30
Study 31474719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of midazolam at doses of 5, 15, and 30 µg/kg
Number of subjects: 19
Study 31474719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of midazolam at doses of 15, 50, and 100 µg/kg
Number of subjects: 19
Study 31474719 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of midazolam after oral administration
Number of subjects: 19
Study 28736211 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern neuroscience approach (pain neuroscience education and cognition-targeted exercise therapy)
Number of subjects: 0
Study 28736211 — intervention group
Group type: COMPARATOR
Intervention: Usual care evidence-based physiotherapy
Number of subjects: 0
Study 26078287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 24
Study 26078287 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 24
Study 22819332 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless (FL) technique
Number of subjects: 40
Study 22819332 — intervention group
Group type: COMPARATOR
Intervention: Flap (F) technique
Number of subjects: 40
Study 21127424 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg every 6 hours for 120 hours (5 days)
Number of subjects: 61
Study 21127424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19455620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (10 mg) with Tadalafil (40 mg QD)
Number of subjects: 26
Study 19455620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (40 mg) with Ambrisentan (10 mg QD)
Number of subjects: 26
Study 19455620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ambrisentan and Tadalafil
Number of subjects: 26
Study 16791807 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC therapy
Number of subjects: 27
Study 16791807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 15646031 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic pearls (GP) 250 mg per day for 2 months
Number of subjects: 20
Study 15646031 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive individuals)
Number of subjects: 20
Study 11198728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10-40 mg)
Number of subjects: 161
Study 11198728 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5-10 mg)
Number of subjects: 161
Study 11198728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 161
Study 9299672 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (n = 44)
Number of subjects: 66
Study 9299672 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (n = 43)
Number of subjects: 66
Study 9299672 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 66
Study 9299672 — intervention group
Group type: COMPARATOR
Intervention: Change in WGTT
Number of subjects: 66
Study 8285333 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 2.5 mg
Number of subjects: 0
Study 8285333 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia using diamorphine
Number of subjects: 0
Study 3505874 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (life circumstances at age 40 reviewed)
Number of subjects: 362
Study 3505874 — intervention group
Group type: COMPARATOR
Intervention: Control group (completed personality inventory twice under standard directions)
Number of subjects: 362
Study 29117913 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Intervention for Depressed Patients with Chronic Obstructive Pulmonary Disease (PID‐C)
Number of subjects: 101
Study 29117913 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem‐Solving Adherence (PSA) intervention
Number of subjects: 101
Study 29117913 — intervention group
Group type: COMPARATOR
Intervention: Control group (PID‐C vs PSA)
Number of subjects: 101
Study 28139161 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Aloe vera gel extract (AGE) for 5 weeks
Number of subjects: 180
Study 28139161 — intervention group
Group type: COMPARATOR
Intervention: Control group (AGE) for 5 weeks
Number of subjects: 180
Study 25585050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-oriented meditation (8-week duration)
Number of subjects: 0
Study 25585050 — intervention group
Group type: COMPARATOR
Intervention: Control group with alcohol dependence
Number of subjects: 0
Study 23545908 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-lightening cream (SLC) with 4% hydroquinone (HQ)
Number of subjects: 20
Study 23545908 — intervention group
Group type: COMPARATOR
Intervention: Triple combination cream (TCC) with 4% hydroquinone (HQ), 0.05% tretinoin, and 0.01% fluocinolone acetonide
Number of subjects: 20
Study 23545908 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-lightening cream (SLC)
Number of subjects: 20
Study 23545908 — intervention group
Group type: COMPARATOR
Intervention: Triple combination cream (TCC)
Number of subjects: 20
Study 23545908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both creams
Number of subjects: 20
Study 20739557 — intervention group
Group type: EXPERIMENTAL
Intervention: Context group (negative expectation)
Number of subjects: 38
Study 20739557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 38
Study 17976226 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring (available data)
Number of subjects: 160
Study 17976226 — intervention group
Group type: COMPARATOR
Intervention: BIS monitoring (concealed)
Number of subjects: 160
Study 16991077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 232
Study 16991077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 232
Study 15050006 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TCC
Number of subjects: 91
Study 15050006 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study 11444449 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 300 microg
Number of subjects: 60
Study 11444449 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.5 mL
Number of subjects: 60
Study 11444449 — intervention group
Group type: EXPERIMENTAL
Intervention: IT neostigmine 50 microg
Number of subjects: 60
Study 9505738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane group
Number of subjects: 60
Study 9505738 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (2 x 250 mg) plus codeine (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin plus ibuprofen (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2 x 250 mg) plus penicillin (2 x 250 mg)
Number of subjects: 588
Study 7996111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 3344883 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic internal and external shoulder rotation
Number of subjects: 22
Study 3344883 — intervention group
Group type: COMPARATOR
Intervention: Eccentric isokinetic internal and external shoulder rotation
Number of subjects: 22
Study 31957958 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous gel with TriHex peptides
Number of subjects: 5
Study 31957958 — intervention group
Group type: COMPARATOR
Intervention: Standard skin regimen
Number of subjects: 5
Study 29746713 — intervention group
Group type: EXPERIMENTAL
Intervention: SCY-078 (1250 mg loading dose on day 1 followed by 750 mg once daily for 7 days)
Number of subjects: 0
Study 29746713 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg single oral dose)
Number of subjects: 0
Study 28081962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (5‐fluorouracil, leucovorin, irinotecan)
Number of subjects: 367
Study 28081962 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (5‐fluorouracil, leucovorin, irinotecan)
Number of subjects: 367
Study 28081962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 367
Study 28081962 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 367
Study 26242213 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-TAVR (Transfemoral TAVR)
Number of subjects: 531
Study 26242213 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-TAVR (Transapical TAVR)
Number of subjects: 531
Study 24568171 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 percent hydrogen-peroxide whitening strips (Strip group)
Number of subjects: 45
Study 24568171 — intervention group
Group type: COMPARATOR
Intervention: In-office light plus 25 percent hydrogen-peroxide whitening gel treatment (In-office group)
Number of subjects: 45
Study 21161543 — intervention group
Group type: EXPERIMENTAL
Intervention: Inert sock liner
Number of subjects: 0
Study 21161543 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete occlusion with a water vapor impermeable wet dressing
Number of subjects: 0
Study 21161543 — intervention group
Group type: COMPARATOR
Intervention: Conventional skin care methods
Number of subjects: 0
Study 21161543 — intervention group
Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 0
Study 18272931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/d GPLC
Number of subjects: 32
Study 18272931 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d GPLC
Number of subjects: 32
Study 18272931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16494566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practitioners
Number of subjects: 20
Study 16494566 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (non-meditators)
Number of subjects: 20
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nursing care
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Respite services
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networks and activity enhancement
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving and education
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Group work
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted services delivered solely to carers
Number of subjects: 0
Study 12597468 — intervention group
Group type: COMPARATOR
Intervention: Randomized control trial (RCT)
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Single group methodology
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator feedback
Number of subjects: 0
Study 12597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evidence
Number of subjects: 0
Study 11092410 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU cholecalciferol/day for 2 years
Number of subjects: 79
Study 11092410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 9352147 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect antiglobulin test with xylene eluates
Number of subjects: 35